Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives $32.00 Consensus Price Target from Brokerages

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $32.00.

Several analysts recently commented on the stock. Wall Street Zen cut shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. Zacks Research raised shares of Odyssey Therapeutics to a “hold” rating in a report on Wednesday, June 3rd. TD Cowen initiated coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued a “buy” rating for the company. Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating for the company. Finally, Wedbush started coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price target on the stock.

Odyssey Therapeutics Stock Performance

ODTX opened at $16.61 on Friday. Odyssey Therapeutics has a 12 month low of $15.35 and a 12 month high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its quarterly earnings data on Wednesday, June 17th. The company reported $999.00 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.31) by $1,000.31.

Insider Activity

In other Odyssey Therapeutics news, Director Shelley Chu acquired 11,111 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $199,998.00. Following the transaction, the director directly owned 11,111 shares of the company’s stock, valued at approximately $199,998. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Nan (Ln) Li acquired 1,111,111 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $19,999,998.00. Following the completion of the purchase, the director owned 3,333,516 shares in the company, valued at $60,003,288. The trade was a 50.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 4,183,777 shares of company stock valued at $75,319,986 in the last 90 days.